Marshall Gerstein Co-Sponsors 2016 ACI Life Sciences Patents Conference; Labbe and Nielsen to Present

February 23, 2016
New York, NY

Marshall, Gerstein & Borun LLP is pleased to co-sponsor the ACI Life Sciences Patents Conference at the DoubleTree Times Square in New York, NY, on February 23-24, 2016. IP Litigation partners John R. Labbe and Matthew C. Nielsen will each participate in a panel discussion during the conference. For more information about the conference, click here.

Tuesday, February 23, 9:30 a.m. – “The Year of the Biosimilar: Refining Current Life Sciences Patent Strategies and Formulating a Multi-Faceted Approach for Innovators and Biosimilars Manufacturers”


  • John R. Labbe, Partner, Marshall, Gerstein & Borun LLP
  • David I. Gindler, Partner, Irell & Manella LLP
  • Jennifer Gordon, Counsel, Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • E. Cary Miller, Partner, Morrison & Foerster LLP (San Diego, CA)
  • Kevin E. Noonan, Partner, McDonnell Boehnen Hulbert & Berghoff LLP

Panelists will discuss multiple topics surrounding biosimilars, including biologics and biologic patenting strategies, how current IP case law will shape claiming and litigating biosimilars, and updates on the first BPCIA cases and the opting- in / opting-out debate: Sandoz v. Amgen and Janssen v. Celltrion.

Wednesday, February 24, 10:15 a.m. – “Antibody Strategy Session: Satisfying the Written Description/Enablement Requirement in Light of Stricter § 112 Standards”


  • Matthew C. Nielsen, Partner, Marshall, Gerstein & Borun LLP
  • Heather Boussios, Assistant General Counsel – IP, Emergent BioSolutions
  • Gloria M. Fuentes, Legal Director, Patents, Merck & Co, Inc.
  • Lawrence S. Perry, Partner, Fitzpatrick, Cella, Harper & Scinto

Panelists in this antibody strategy session will review topics such as supporting your patent claim and securing antibody coverage through adequate written description post-Abbvie v. Janssen, Novozymes, and Nautilus, and overcoming an obviousness rejection – balancing the inherent tension between the need to demonstrate unpredictability and producing an adequate written description.